TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prevalence of definite RHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 10-year CHD risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of prescribed medications
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Predictive efficiency of VEGF status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in eyesight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rates of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of MNFL, RNL and PECCL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in red blood cell concentrate transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Intra‐operative and post‐operative fluid balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unmet needs of cancer survivors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: EQ-5D score difference
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: total healthcare cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean AUC of the spastic region
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: arrhythmia-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in HDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in plasma MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity of 18FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of 18FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients prescribed antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: darbepoetin alfa concentration–time profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PD and safety profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum total and LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breastfeeding rates at 6 weeks postpartum
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of menorrhagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hematocrit levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: pain relief for ipsilateral post‐thoracotomy shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal delivery rate in 24 hours
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Cesarean sections for fetal distress
Endpoint domain: Adverse events/effects
Primary endpoint: plasma magnesium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean serum prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Physiological fall risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve (AUC0-τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration at the end of the dosage interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ECG voltage amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of sgp91(phox)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary isoprostanes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: restenosis rate at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: cumulative patency rates after 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: maximum vitreous dexamethasone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual hematoma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-reported moderate to vigorous physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accelerometer-measured physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak oxygen uptake (VO2Peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in triglyceride concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Waist circumference change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Renal clearance of lithium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Heart rate recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: total recall score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Seropositivity rates for polio types 1, 2, and 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric mean titers of antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Confidence rating for the hysteroscopic view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reversion to nondiabetic status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative incidence of sore throat
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative incidence of vocal cord injuries
Endpoint domain: Adverse events/effects
Primary endpoint: Aerobic capacity (peak VO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tissue AGEs (skin autofluorescence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diastolic function (mean E' and E/E')
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endothelial function improvement (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Potency of levobupivacaine and ropivacaine for epidural analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-123 BMIPP defect score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increased understanding of challenges and difficulties
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: HBsAg seroclearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of clinically important findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of malignancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: False-positive rate
Endpoint domain: Adverse events/effects
Primary endpoint: corrected Thrombolysis in Myocardial Infarction frame counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: normalized peak signal intensities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of myocardial segments with abnormal wall thickening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Psoriasis Area and Severity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in understanding
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: increase in knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: patient preference for PVM
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Symptom and physical sign score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of bronchodilation within 5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage increase in FEV1 during 120-min post-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: submaximal exercise‐induced coronary artery blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: resting coronary artery blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Knowledge of the illness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Average serum glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of immune-inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Metabolic disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Children's self-performed tooth brushing ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of acid-induced hypersensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median visual analogue scale score for acid-induced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: PAGI-QOL total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PAGI-SYM total score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Successful gut cleansing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient ratings of acceptability and taste
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Image quality rating of the transition zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Syndrome Scale (PANSS) positive factor endpoint scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PANSS emotional distress factor endpoint score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary anatomical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WHOQOL-BREF social relationships domain scores
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Successful intubation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intubating conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time of oral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exercise and physical activity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Four-year compliance rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Moderate‐to‐severe gastroenteritis within 14 days after enrollment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Assessment score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for training modality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: risk of perioperative angioedema
Endpoint domain: Adverse events/effects
Primary endpoint: Roux-loop obstruction
Endpoint domain: Adverse events/effects
Primary endpoint: Positive culture results after surgery
Endpoint domain: Adverse events/effects
Primary endpoint: immediate postoperative VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-h opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to ultrasound therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: On-demand opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: stabilometry results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability as assessed by adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of glaucoma referrals
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: emotional attitude
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of 30-day readmission
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Dyspnea improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frontal lobe volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: total brain volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean pupil diameter under mesopic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pupil diameter under scotopic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation between Goldmann perimeter and Procyon Video Pupillometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-ACT score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score during introduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC during the entire procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: mean maximum plasma concentration (C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: area under the plasma concentration‐time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: growth rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of maternal fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: anesthetics consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of TLE3 positive tumours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Movements of the hands, arms, and head
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean reduction in percent body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: decrease in plasma insulin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: improvement in insulin sensitivity (HOMA-IR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: lasting pain relief
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Vascular function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Detection of metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of nevirapine resistance mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total:HDL cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serum IGF‐I concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Urinary Na/K response to amiloride
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Intranasal amiloride-sensitive potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of cerebral microemboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cortical thickness of the tibia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum 25OHD concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of patient care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continuity of care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of resident education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: need for transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Diagnostic time reduction
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Repeat evaluations for recurrent chest pain
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Identification of coronary disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum magnesium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of blood units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of wound exsudation and bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of subcutaneous hematomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ALDS improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QoL deterioration in PDQ-39
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weaning rate within 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PA at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ALB at Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: diarrhea-related hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Target Lesion Failure (TLF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: time to full deflation of the TRB with haemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical and mental health components of the SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of new surgically eligible basal-cell carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Size of existing clinically significant basal-cell carcinomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Discontinuation of drug treatment due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rate of sentinel nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of detection methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of detection methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: B(a)P‐DNA adduct levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevention of PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of sick leave episodes
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: time to first day of sick leave episode
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: relative change in residual platelet reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: LDL-Chol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HDL-Chol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: complete headache resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse event incidence
Endpoint domain: Adverse events/effects
Primary endpoint: energy metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: absolute haematoma volume on computed tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morning alertness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total HOME score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Child-rearing practices scores
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Average maximal standardized uptake value (SUVmax) in the colon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DD3 mRNA expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes